TechCrunch : David Sacks is done as AI czar — here’s what he’s doing instead

David Sacks is done as AI czar — here’s what he’s doing instead

David Sacks has used up his days as Donald Trump’s AI and crypto czar.

Speaking with Bloomberg on Thursday, the longtime entrepreneur, investor, and podcaster confirmed that his non-consecutive 130-day stint as a special government employee is over and that he’s moving on to co-chair the President’s Council of Advisors on Science and Technology (PCAST) alongside senior White House technology adviser Michael Kratsios.

“I think moving forward as co-chair of PCAST, I can now make recommendations on not just AI but an expanded range of technology topics,” he told Bloomberg via a video interview. “So yes, this is how I’ll be involved moving forward.”

What that means in practice is Sacks will be much further from the power center in Washington than since the outset of this second Trump administration. As AI czar, Sacks had a direct line to Trump and a hand in shaping policy. PCAST is a federal advisory body, so while it studies issues, produces reports, and sends recommendations up the chain, it doesn’t make policy.

The council has existed in some form since FDR, though Sacks made a point to Bloomberg of noting that this particular iteration has “the most star power of any group like this” ever assembled, and it’s hard to argue he’s wrong. The initial 15 members include Nvidia’s Jensen Huang, Meta’s Mark Zuckerberg, Oracle’s Larry Ellison, Google co-founder Sergey Brin, Marc Andreessen, AMD’s Lisa Su, and Michael Dell, among others. (That’s a lot of billionaires.)

Sacks told Bloomberg the council will take up AI, advanced semiconductors, quantum computing, and nuclear power, and that near-term attention will go toward pushing Trump’s national AI framework, released just last week. The framework is aimed at replacing what Sacks described to Bloomberg as a mess of conflicting state-level rules. “You’ve got 50 different states regulating this in 50 different ways,” he said, “and it’s creating a patchwork of regulation that’s difficult for our innovators to comply with.”

What Sacks didn’t address head-on was why the transition is happening now and whether his recent comments were a factor. Earlier this month, on the popular “All In” podcast that he co-hosts, Sacks publicly urged the administration to find an exit from the U.S.-backed war with Iran, walking through a set of worsening scenarios — attacks on oil infrastructure in neighboring countries, the destruction of desalination plants, the possibility of nuclear use by Israel — and calling for a polite way out. Trump responded by telling reporters that Sacks hadn’t spoken to him about the war. (The U.S.-Israel war on Iran has now been going on for approximately 27 days.)

Asked about the podcast episode on Thursday by Bloomberg, Sacks figuratively threw his hands in the air: “I’m not on the foreign policy team or the national security team,” he said, adding that his podcast comments represented his personal view, not an official one.

For all the marquee names Sacks is bringing to PCAST, it’s worth reflecting on what the council has historically been, which is an advisory body with some influence in some administrations and almost none in others.

President Obama’s version was seemingly the most productive on record, churning out 36 reports over eight years — two of which led to concrete policy changes, including an FDA rule that opened the market for over-the-counter hearing aids.

President Trump’s first-term council, by contrast, took nearly three years just to name its first members, produced a handful of reports, and made no particular mark, while President Biden’s council skewed heavily academic — Nobel laureates, MacArthur fellows, National Academy members — and issued a modest number of reports before the administration ended.

The current PCAST is a completely different animal, built almost entirely from the executive suites of the companies shaping the technology it will advise on.

Now, Sacks is again one of those unencumbered executives, free to resume his life as an investor and entrepreneur. A spokesperson for Craft Ventures, the firm Sacks co-founded and where he remains a partner, has not yet responded to related questions about next steps; TechCrunch reported last year on the ethics waivers Sacks obtained to maintain financial stakes in AI and crypto companies while shaping federal policy in both areas — an arrangement that drew sharp criticism from ethics experts and lawmakers.

FT : Nestlé pushes ahead with €5bn Perrier and San Pellegrino deal

Nestlé pushes ahead with €5bn Perrier and San Pellegrino deal
CD&R, KKR and PAI among firms through to next round in sale of 50% stake in water division

Nestlé’s sale of a multibillion euro stake in its water business has progressed, with a handful of private equity firms through to the next stage of bidding, according to people familiar with the matter.

The investment groups CD&R, KKR and PAI are through to the next round in a deal for a 50 per cent stake in the unit that could value the entire business at roughly €5bn, according to people familiar with the matter. Platinum Equity has also shown interest in the deal.

Nestlé has been working with investment bankers to explore a stake sale in its European water business, which includes brands such as San Pellegrino, Perrier and Acqua Panna. Initial bids were due earlier this month.

Its pursuit of a deal comes as the Swiss group undertakes a strategic overhaul led by new chief executive Philipp Navratil, who is seeking to turn around the struggling consumer goods group.

He has reorganised Nestlé to focus on four new categories: coffee, petcare, nutrition, and food and snacks. It has turned to private equity groups for other asset sales, including offloading the rest of its ice cream assets to joint venture partner Froneri that Nestlé jointly owns with PAI.

Since his appointment in September, Navratil has announced 16,000 job cuts over the next 18 months. He is also pressing ahead with plans to sell its vitamins and supplement brands.

Nestlé is not the only consumer group seeking to shed slower growing brands.

Unilever is also in discussions to sell its food division to spice and sauce maker McCormick, in a megadeal that would complete the consumer goods giant’s near decade-long pivot to faster growing beauty and personal care brands.

In 2021, Nestlé agreed a $4bn deal with US private equity firm One Rock Capital to sell its North American water business, which included the Poland Spring and Pure Life brands.

Nestlé, CD&R, KKR and PAI declined to comment. Platinum did not immediately respond to a request for comment.

FT : Blackstone in advanced talks for aerospace parts maker Senior

Blackstone in advanced talks for aerospace parts maker Senior
Private capital group and industrial investor Tinicum in talks with FTSE 250 company

Blackstone is part of a consortium in advanced talks to take control of UK aerospace parts supplier Senior, according to people familiar with the matter.

The private capital group and industrial investor Tinicum are progressing and could propose an offer acceptable to Senior’s board in the coming weeks, the people said. They cautioned that no decisions had been taken yet and talks could still shift or fall apart.

Blackstone and Tinicum are among a number of bidders that have shown interest in Senior, alongside the private equity groups Advent International and Arcline Investment Management.

The Blackstone-Tinicum consortium had emerged as a frontrunner in recent days, according to the people, although they cautioned that the situation could still change.

Earlier on Friday, Senior said that it remained in discussions with Advent and had agreed an extension to the investment group’s deadline to make a firm offer. Advent had previously proposed £2.72 a share but its offer was rejected.

The deadlines for the other two rival parties to make firm offers are due to expire early next week.

Senior’s shares surged in late February after it disclosed that it had received multiple offers and had hired investment banks to lead talks. The stock was trading on Friday afternoon at £2.77, valuing the company at £1.16bn.

The FTSE 250 group specialises in making ducts and valves to control fuel consumption for customers in the aerospace, defence and energy markets. If acquired, it would mark the latest in a series of British industrial groups to be taken over by both industrial and private equity buyers.

Advent bought Cobham and Ultra Electronics, while Meggitt was acquired by US industrial group Parker Hannifin.

Senior and Blackstone declined to comment. Tinicum did not immediately respond to a request for comment.

>>> Europe : Brokers Upgrades & Downgrades - 27th of March 2026 V3(++)

>>> Up
* Air Liquide Raised to Equal-Weight at Morgan Stanley
* Aker BP Raised to Buy at Pareto Securities; PT 400 kroner (+)
* Amadeus Raised to Buy at Intermoney Valores; PT 70 euros
* Atlantic Lithium Raised to Neutral at Macquarie; PT 16.56 pence
* Bellway Raised to Buy at Peel Hunt; PT 2,380 pence
* Berkeley Raised to Buy at BofA
* Billerud Raised to Buy at Pareto Securities; PT 93 kronor
* Brown-Forman Raised to Neutral at Citi; PT $28
* Brown-Forman Raised to Neutral at JPMorgan; PT $27
* BT PT Raised to 175 pence from 140 pence at Citi
* Derwent London Raised to Equal-Weight at Barclays
* DNB Bank Raised to Hold at Danske Bank Markets; PT 290 kroner (++)
* Eni Raised to Outperform at Mediobanca SpA; PT 28 euros
* Evonik Raised to Overweight at Morgan Stanley; PT 18 euros
* Intesa Sanpaolo Raised to Buy at Goldman; PT 6.90 euros
* Ion Beam PT Raised to 18.50 euros at Bank Degroof Petercam (++)
* JM Raised to Buy at SEB Equities; PT 140 kronor
* Knorr-Bremse Raised to Buy at BofA
* Marks Electrical Group Raised to Buy at Cavendish; PT 55 pence
* MONY Group Raised to Buy at Jefferies; PT 230 pence
* National Bank of Greece Raised to Buy at Alpha Finance
* Nemetschek Raised to Hold at DZ Bank; PT 70 euros (+)
* Novonesis Raised to Buy at Rothschild & Co Redburn
* Pernod Ricard Raised to Hold at Deutsche Bank; PT 65 euros (+)
* PORR Raised to Buy at MP Capital Markets (+)
* Savills Raised to Buy at UBS; PT 1,040 pence
* Securitas Raised to Buy at Pareto Securities; PT 173 kronor
* SMA Solar PT Raised to 52 euros at Bankhaus Metzler (+)
* SOL Raised to Buy at Kepler Cheuvreux (+)
* Thermo Fisher Rated New Buy at DZ Bank; PT $610 (+)
* Vallourec PT Raised to 29 euros from 23.60 euros at Bernstein
* Var Energi Raised to Buy at Pareto Securities; PT 55 kroner (++)

>>> Down
* Aixtron Cut to Sell at mwb research AG; PT 30 euros (++)
* Banco BPM Cut to Neutral at Goldman; PT 14.30 euros
* Barry Callebaut Cut to Underweight at Barclays
* Beiersdorf Cut to Neutral at Goldman; PT 90 euros
* Boliden Cut to Hold at Deutsche Bank; PT 580 kronor
* Corbion Cut to Equal-Weight at Barclays; PT 20 euros
* Elisa Cut to Underweight at JPMorgan; PT 39 euros
* EQT Cut to Underperform at Autonomous (+)
* Equinor Cut to Hold at Pareto Securities; PT 400 kroner (++)
* Ericsson Cut to Neutral at Grupo Santander; PT 113 kronor (+)
* FACC Cut to Hold at Kepler Cheuvreux; PT 14.70 euros (++)
* Future Plc Cut to Hold at Jefferies; PT 466 pence
* Galp Cut to Underperform at Mediobanca SpA; PT 20.50 euros
* Givaudan Cut to Equal-Weight at Barclays; PT 3,050 Swiss francs
* GVS PT Cut to 4 euros from 5.30 euros at Banca Akros (++)
* IAG PT Cut to 355 pence from 370 pence at UBS (++)
* Lanxess Cut to Equal-Weight at Morgan Stanley; PT 20 euros
* Nokia Cut to Underperform at Grupo Santander; PT 6.85 euros (+)
* Ontex Cut to Underperform at Oddo BHF; PT 3.70 euros
* PORR Cut to Accumulate at Erste Group; PT 39.50 euros (+)
* Saipem Cut to Neutral at Mediobanca SpA; PT 3.60 euros
* SKF Cut to Underperform at BofA
* Sofina PT Cut to 290 euros at Bank Degroof Petercam (++)
* Syensqo Cut to Equal-Weight at Morgan Stanley; PT 50 euros
* TotalEnergies Cut to Neutral at Mediobanca SpA; PT 80 euros
* Yubico Cut to Hold at ABG; PT 35 kronor

>>> Initiation
* ABN Amro ADRs Rated New Underperform at BNP Paribas; PT $34.50 (+)
* AIB Group ADRs Rated New Neutral at BNP Paribas; PT $23.20 (+)
* Arjo Rated New Neutral at SB1 Markets; PT 27 kronor
* Bank of Ireland ADRs Rated New Outperform at BNP Paribas (+)
* Barclays ADRs Rated New Outperform at BNP Paribas; PT $29.20 (+)
* BBVA ADRs Rated New Underperform at BNP Paribas; PT $21.10 (+)
* Bittium Rated New Buy at Stifel; PT 40 euros
* BPER Banca Reinstated Neutral at Goldman; PT 13.70 euros
* CaixaBank ADRs Rated New Outperform at BNP Paribas; PT $5 (+)
* Commerzbank ADRs Rated New Outperform at BNP Paribas; PT $45 (+)
* Credit Agricole ADRs Rated New Neutral at BNP Paribas; PT $11 (+)
* DNB Bank ADRs Rated New Neutral at BNP Paribas; PT $34.70
* Electrolux Reinstated Neutral at Goldman; PT 65 kronor
* HSBC ADRs Rated New Outperform at BNP Paribas; PT $100.50 (+)
* ING ADRs Rated New Outperform at BNP Paribas; PT $34.50 (+)
* Julius Baer ADRs Rated New Outperform at BNP Paribas; PT $18.50 (+)
* KBC ADRs Rated New Neutral at BNP Paribas; PT $72.60 (+)
* KGHM Rated New Reduce at Kepler Cheuvreux; PT 185.12 zloty (+)
* Lloyds ADRs Rated New Neutral at BNP Paribas; PT $6 (+)
* Meko Rated New Neutral at SB1 Markets; PT 75 kronor
* Monte Paschi Reinstated Buy at Goldman; PT 10.10 euros
* NatWest ADRs Rated New Neutral at BNP Paribas; PT $17.90
* Nordea Bank ADRs Rated New Outperform at BNP Paribas; PT $23.20 (+)
* Novagold Resources Rated New Speculative Buy at Canaccord
* Palfinger Rated New Buy at Kepler Cheuvreux; PT 48 euros (+)
* Santander ADRs Rated New Outperform at BNP Paribas; PT $15.10 (+)
* Standard Chartered ADRs Rated New Neutral at BNP Paribas (+)
* SEB Reinstated Buy at Goldman; PT 64 euros
* SocGen ADRs Rated New Outperform at BNP Paribas; PT $20.50 (+)
* Strabag Rated New Buy at Bankhaus Metzler; PT 120 euros (+)
* Swedbank ADRs Rated New Neutral at BNP Paribas; PT $40.70 (+)

>>> Call
* Barclays Sees S&P 500 Jump Up to 5% on Iran Deal: Equity Insight
* Fraport Kept at Sell as Mwb Notes Terminal 2 Reopening Delay (++)
* Goldman Sachs Upgrades Intesa, Initiates Paschi at Buy (+)
* JM Rallies as SEB Equities Upgrades on Limited Downside Risk (++)
* Mediobanca Upgrades Eni, Cuts Total and Galp on Oil Outlook (++)
* Morgan Stanley Favors Upstream in Chemicals, BASF Now Top Pick
* Netcompany Set to Gain Following Margin Upgrade: Morgan Stanley
* SOL Jumps as Analysts Flag FY Sales Increase, Margin Expansion (++)
* UK Homebuilders Have Estimates Cut at BofA; Berkeley Upgraded (+)
* Vallourec PT Lifted at Bernstein on North America Inflection

>>> GOOGLE TURBOQUANT — INFERENCE EFFICIENCY BREAKTHROUGH

GOOGLE TURBOQUANT — INFERENCE EFFICIENCY BREAKTHROUGH
KV Cache −6x Memory | 8x Attention Speedup | Zero Accuracy Loss

■ WHAT IT IS
Training-free compression algo targeting the KV cache (working memory in LLMs).

Compresses each cache value from 16 bits → 3 bits. No retraining required.

Drop-in on production models. PyTorch/MLX ports live within 24h of release.

■ HOW IT WORKS
Stage 1 – PolarQuant: rotates KV vectors into polar coords, eliminating per-block normalization overhead (the 1-2 bit tax that defeats most compression).
Stage 2 – QJL: reduces vectors to sign bits (+1/-1) via Johnson-Lindenstrauss Transform. Zero memory overhead. High-precision query estimator preserves attention accuracy.

Result: approaches information-theoretic optimum. Online, data-oblivious,
accelerator-friendly.

■ BENCHMARKS (H100)
- 4-bit impl: 8x speedup on attention logit computation vs unquantized 32-bit
- 3-bit: 6x KV cache reduction, zero degradation on LongBench / NIAH / RULER / L-Eval

Community test (MLX / Qwen3.5-35B, 8.5K–64K ctx): 100% output match at 2.5-bit

■ MARKET REACTION
SK Hynix -6.0% KRX
Kioxia -5.9% TSE
SanDisk -5.7% NASDAQ
Samsung -4.9% KRX
WDC -4.7% NASDAQ
Micron -3.0% NASDAQ

■ ANALYST SPLIT
- Wells Fargo (Rocha): "Directly attacking the cost curve. Calls into question how much memory capacity is needed." — bearish on near-term demand; adoption TBD.
- Morgan Stanley: does not touch model weights or training HBM. Bullish.
- SemiAnalysis (Wang): bottleneck relief → more capable models → more hardware.
- Quilter Cheviot: "Evolutionary, not revolutionary." Cyclical sell-off, not structural.
- Cloudflare CEO Prince: "Google's DeepSeek moment."

■ MY VIEW
Overreaction. TurboQuant is inference-only — training HBM demand (the supercycle driver) is entirely unaffected. Jevons dynamics apply: 6x cheaper inference → longer contexts, more agents, more RAG pipelines deployed.
MU/SK Hynix weakness is technical/positional, not a demand inflection.

Watch Q2 datacenter capex guidance from AWS/Azure/GOOGL as the real signal.

>>> Europe : Brokers Upgrades & Downgrades - 27th of March 2026 V2(+)

>>> Up
* Air Liquide Raised to Equal-Weight at Morgan Stanley
* Amadeus Raised to Buy at Intermoney Valores; PT 70 euros
* Atlantic Lithium Raised to Neutral at Macquarie; PT 16.56 pence
* Bellway Raised to Buy at Peel Hunt; PT 2,380 pence
* Berkeley Raised to Buy at BofA
* Billerud Raised to Buy at Pareto Securities; PT 93 kronor
* Brown-Forman Raised to Neutral at Citi; PT $28
* Brown-Forman Raised to Neutral at JPMorgan; PT $27
* BT PT Raised to 175 pence from 140 pence at Citi
* Derwent London Raised to Equal-Weight at Barclays
* Eni Raised to Outperform at Mediobanca SpA; PT 28 euros
* Evonik Raised to Overweight at Morgan Stanley; PT 18 euros
* Intesa Sanpaolo Raised to Buy at Goldman; PT 6.90 euros
* JM Raised to Buy at SEB Equities; PT 140 kronor
* Knorr-Bremse Raised to Buy at BofA
* Marks Electrical Group Raised to Buy at Cavendish; PT 55 pence
* MONY Group Raised to Buy at Jefferies; PT 230 pence
* National Bank of Greece Raised to Buy at Alpha Finance
* Nemetschek Raised to Hold at DZ Bank; PT 70 euros (+)
* Novonesis Raised to Buy at Rothschild & Co Redburn
* Pernod Ricard Raised to Hold at Deutsche Bank; PT 65 euros (+)
* PORR Raised to Buy at MP Capital Markets (+)
* Savills Raised to Buy at UBS; PT 1,040 pence
* Securitas Raised to Buy at Pareto Securities; PT 173 kronor
* SMA Solar PT Raised to 52 euros at Bankhaus Metzler (+)
* SOL Raised to Buy at Kepler Cheuvreux (+)
* Thermo Fisher Rated New Buy at DZ Bank; PT $610 (+)
* Vallourec PT Raised to 29 euros from 23.60 euros at Bernstein

>>> Down
* Banco BPM Cut to Neutral at Goldman; PT 14.30 euros
* Barry Callebaut Cut to Underweight at Barclays
* Beiersdorf Cut to Neutral at Goldman; PT 90 euros
* Boliden Cut to Hold at Deutsche Bank; PT 580 kronor
* Corbion Cut to Equal-Weight at Barclays; PT 20 euros
* Elisa Cut to Underweight at JPMorgan; PT 39 euros
* EQT Cut to Underperform at Autonomous (+)
* Ericsson Cut to Neutral at Grupo Santander; PT 113 kronor (+)
* Future Plc Cut to Hold at Jefferies; PT 466 pence
* Galp Cut to Underperform at Mediobanca SpA; PT 20.50 euros
* Givaudan Cut to Equal-Weight at Barclays; PT 3,050 Swiss francs
* Lanxess Cut to Equal-Weight at Morgan Stanley; PT 20 euros
* Nokia Cut to Underperform at Grupo Santander; PT 6.85 euros (+)
* Ontex Cut to Underperform at Oddo BHF; PT 3.70 euros
* PORR Cut to Accumulate at Erste Group; PT 39.50 euros (+)
* Saipem Cut to Neutral at Mediobanca SpA; PT 3.60 euros
* SKF Cut to Underperform at BofA
* Syensqo Cut to Equal-Weight at Morgan Stanley; PT 50 euros
* TotalEnergies Cut to Neutral at Mediobanca SpA; PT 80 euros
* Yubico Cut to Hold at ABG; PT 35 kronor

>>> Initiation
* ABN Amro ADRs Rated New Underperform at BNP Paribas; PT $34.50 (+)
* AIB Group ADRs Rated New Neutral at BNP Paribas; PT $23.20 (+)
* Arjo Rated New Neutral at SB1 Markets; PT 27 kronor
* Bank of Ireland ADRs Rated New Outperform at BNP Paribas (+)
* Barclays ADRs Rated New Outperform at BNP Paribas; PT $29.20 (+)
* BBVA ADRs Rated New Underperform at BNP Paribas; PT $21.10 (+)
* Bittium Rated New Buy at Stifel; PT 40 euros
* BPER Banca Reinstated Neutral at Goldman; PT 13.70 euros
* CaixaBank ADRs Rated New Outperform at BNP Paribas; PT $5 (+)
* Commerzbank ADRs Rated New Outperform at BNP Paribas; PT $45 (+)
* Credit Agricole ADRs Rated New Neutral at BNP Paribas; PT $11 (+)
* DNB Bank ADRs Rated New Neutral at BNP Paribas; PT $34.70
* Electrolux Reinstated Neutral at Goldman; PT 65 kronor
* HSBC ADRs Rated New Outperform at BNP Paribas; PT $100.50 (+)
* ING ADRs Rated New Outperform at BNP Paribas; PT $34.50 (+)
* Julius Baer ADRs Rated New Outperform at BNP Paribas; PT $18.50 (+)
* KBC ADRs Rated New Neutral at BNP Paribas; PT $72.60 (+)
* KGHM Rated New Reduce at Kepler Cheuvreux; PT 185.12 zloty (+)
* Lloyds ADRs Rated New Neutral at BNP Paribas; PT $6 (+)
* Meko Rated New Neutral at SB1 Markets; PT 75 kronor
* Monte Paschi Reinstated Buy at Goldman; PT 10.10 euros
* NatWest ADRs Rated New Neutral at BNP Paribas; PT $17.90
* Nordea Bank ADRs Rated New Outperform at BNP Paribas; PT $23.20 (+)
* Novagold Resources Rated New Speculative Buy at Canaccord
* Palfinger Rated New Buy at Kepler Cheuvreux; PT 48 euros (+)
* Santander ADRs Rated New Outperform at BNP Paribas; PT $15.10 (+)
* Standard Chartered ADRs Rated New Neutral at BNP Paribas (+)
* SEB Reinstated Buy at Goldman; PT 64 euros
* SocGen ADRs Rated New Outperform at BNP Paribas; PT $20.50 (+)
* Strabag Rated New Buy at Bankhaus Metzler; PT 120 euros (+)
* Swedbank ADRs Rated New Neutral at BNP Paribas; PT $40.70 (+)

>>> Call
* Barclays Sees S&P 500 Jump Up to 5% on Iran Deal: Equity Insight
* Goldman Sachs Upgrades Intesa, Initiates Paschi at Buy (+)
* Morgan Stanley Favors Upstream in Chemicals, BASF Now Top Pick
* Netcompany Set to Gain Following Margin Upgrade: Morgan Stanley
* UK Homebuilders Have Estimates Cut at BofA; Berkeley Upgraded (+)
* Vallourec PT Lifted at Bernstein on North America Inflection

>>> NOVARTIS / EXCELLERGY — $2BN DEAL | READ-ACROSS TO DBV

NOVARTIS / EXCELLERGY — $2BN DEAL | READ-ACROSS TO DBV

The Deal in Brief
Excellency (Palo Alto, CA) is developing a novel class called trifunctional Effector Cell Response Inhibitors (ECRIs) — lead asset Exl-111 is a trifunctional ECRI targeting the IgE axis, currently in Phase 1. Total consideration is up to $2bn in upfront + milestones; close expected H2 2026 subject to regulatory approvals.

Strategic Framing for Novartis
The deal follows Novartis's agreement last week to acquire a breast-cancer candidate from Synnovation Therapeutics for up to $3bn — a clear pattern of dealmaking to fill the pipeline and offset patent expirations. The food allergy / immunology space is now a declared strategic priority for Basel.

READ-ACROSS TO DBV TECHNOLOGIES
This is unambiguously positive for DBV and here's why:

1. Strategic validation of food allergy at Phase 1 = $2bn Novartis just paid up to $2bn for a Phase 1 asset in food allergy. DBV has a Phase 3-proven asset (VITESSE positive Dec 2025) with a BLA coming in H1 2026. The implied risk-adjusted premium on DBV's VIASKIN® is enormous by comparison. This deal puts a floor — and arguably a ceiling test — on what a validated late-stage peanut allergy platform should be worth to a large pharma acquirer.

2. IgE axis = direct competitive + validation overlap Exl-111 is designed to disarm allergic effector cells at the source of activation by targeting the IgE axis. DBV's VIASKIN® patch works via epicutaneous immunotherapy and also modulates the IgE-mediated allergic response in peanut-allergic children. These are mechanistically adjacent — meaning Novartis just validated the target biology DBV is attacking.

3. Competitive landscape — important nuance Exl-111 is Phase 1 with a distinct mechanism (small molecule-like effector cell inhibition vs. DBV's antigen desensitization). They are potentially complementary rather than directly competitive — different treatment paradigms (inhibit mast cell activation vs. build tolerance). DBV retains the only late-stage patch desensitization approach.

4. M&A re-rating catalyst for DBV The Novartis move joins Sanofi/Regeneron's Dupixent (eosinophilic/atopic axis), AZ's Tezspire, and now this ECRI deal — all underscoring Big Pharma's appetite for allergy immunology. DBV is the only de-risked, BLA-ready peanut allergy asset not yet partnered. M&A optionality on DBV should re-rate after today.

DBV FY2025 NUMBERS — THIS MORNING
Reported yesterday (March 26) — board-approved figures:
Metric FY2025 FY2024
Cash (Dec 31) $194.2m $32.5m
Net loss $147.0m $113.9m
R&D expenses ↑ $27.3m vs prior year —
Operating income (CIR) $5.6m $4.2m
Net loss/share $1.05 $1.17
Cash trajectory: $276.2m in net financing inflows in 2025, driven by the PIPE and ATM. An additional $94m from warrant exercises landed in January 2026 — total liquidity now funds operations into Q2 2027.

The R&D step-up is strategic, not wasteful: $16.1m of the R&D increase was pre-commercial inventory build for VIASKIN® Peanut Patch ahead of a potential approval, and $6.9m went to the COMFORT Toddlers safety study enrollment. DBV is spending like a company preparing for launch — not burning capital aimlessly.

2026 Catalysts: BLA submission for 4-7 year olds H1 2026 (Priority Review eligible); BLA submission for 1-3 year olds H2 2026 under Accelerated Approval Pathway; COMFORT Toddlers topline readout expected.

BOTTOM LINE
The Novartis/Excellergy deal is the most important external read-across for DBV in months. A Big Pharma paying $2bn for a Phase 1 IgE-axis allergy asset on the same day DBV publishes solid balance sheet numbers ($288m effective cash runway into 2027) and confirms imminent BLA filing is close to a perfect storm of re-rating catalysts. The M&A angle in your Courchevel Fiche Biotech on DBV looks even more prescient today.

WSJ : Senate Approves Funding for Most of DHS, Moving to End Airport Crisis

Senate Approves Funding for Most of DHS, Moving to End Airport Crisis
The measure, approved by Democrats and Republicans in the early hours of Friday, now heads to the House

  • The Senate agreed early Friday to fund most of the Department of Homeland Security, excluding ICE and Border Patrol.
  • President Trump said he would sign an executive order to temporarily pay TSA workers, calling it an “emergency situation.”
  • The Senate action followed Democrats rejecting prior DHS funding over immigration enforcement tactics; Trump’s order faces potential court challenges.

WASHINGTON—Senate Republicans and Democrats agreed early Friday to fund most of the Department of Homeland Security, moving to end a standoff over immigration enforcement in Congress that had led to missed paychecks for airport security workers and long lines for travelers.

Shortly after 2 a.m., senators agreed by unanimous consent to approve legislation to fund all of DHS through the end of the fiscal year—except for Immigration and Customs Enforcement and Border Patrol. The measure would provide funding for an assortment of programs, including the Transportation Security Administration, the Coast Guard and the Federal Emergency Management Agency.

The legislation, which didn’t include any changes to immigration enforcement policies, now must be passed by the House, which was expected to act quickly later Friday.

The Senate action came hours after President Trump said he would sign an executive order to free up money to pay TSA workers. Trump said he was instructing Secretary of Homeland Security Markwayne Mullin to pay TSA agents to address what he called an “emergency situation.” Many unpaid security workers have been calling in sick while others have quit, driving delays for airline passengers headed on spring break.

Democrats rejected funding for DHS last month as they sought to block money for ICE and impose tighter rules on immigration-enforcement tactics, such as requiring agents not to wear masks and to obtain judicial warrants before forcing entry into a home.

Senate Republicans and Democrats had worked into the night to reach a deal to fund DHS, aiming to pass legislation before leaving Capitol Hill for a two-week Easter recess. Republicans have a 53-47 majority in the Senate, but advancing legislation typically requires 60 votes in the chamber.

Senate Majority Leader John Thune (R., S.D.) told reporters late Thursday that Trump’s order to pay TSA agents takes “the immediate pressure off” but was a “short-term solution.” Later, he offered the unanimous consent resolution to pass most of the DHS funding after both parties agreed to move forward. No senator objected and the bill passed.

Republicans had already pumped tens of billions of dollars into ICE and border patrol in Trump’s tax package last year, money that will cushion the programs against any cuts to fiscal 2026 spending stemming from the current dispute. Senate Republicans are now expected to try to pass the immigration-enforcement funding through a process called budget reconciliation, which would allow them to pass it with a simple majority.

“We will have other options to get the rest of it done,” Thune said. He said Democrats got “zero reforms” due to the way the fight played out.

Senate Minority Leader Chuck Schumer (D., N.Y.) said he would continue to seek changes to immigration enforcement practices.

“I’m very proud of my caucus,” he told reporters. “My caucus didn’t budge.” He said that Democrats would “fight hard for reforms” and “there will be opportunities.”

After DHS funding lapsed on Feb. 14 and the standoff intensified, Republicans had searched for other ways to fund DHS and pay TSA agents. Republicans said that the Trump administration had already made administrative changes aimed at satisfying Democratic demands, as well as removing Kristi Noem as DHS secretary, following the deaths of two people in encounters with immigration officials in Minnesota.

Democrats for their part argued that Republicans were ignoring their demands for policy changes. They had also put forward measures just funding TSA, which had been blocked by Republicans.

Last week, White House officials said the administration would expand the use of body cameras and limit enforcement activities at sensitive places such as hospitals and schools, and require that officers clearly identify themselves. The officials also pledged to comply with oversight laws, including congressional oversight of detention facilities.